瑞康医药9月9日获融资买入649.83万元，融资余额2.01亿元

Group 1 - The core viewpoint of the news highlights the recent trading performance and financial metrics of Ruikang Pharmaceutical, indicating a slight decline in stock price and specific financing activities [1][2] - As of September 9, Ruikang Pharmaceutical's stock price decreased by 0.68%, with a trading volume of 48.56 million yuan and a net financing purchase of 2.94 million yuan [1] - The company's financing balance is reported at 202 million yuan, which constitutes 4.59% of its market capitalization, indicating a low financing level compared to the past year [1] Group 2 - For the first half of 2025, Ruikang Pharmaceutical reported a revenue of 3.544 billion yuan, reflecting a year-on-year decrease of 12.11%, while the net profit attributable to shareholders was 18.17 million yuan, down 41.45% year-on-year [2] - The company has distributed a total of 393 million yuan in dividends since its A-share listing, with 36.03 million yuan distributed over the past three years [3]